Conatus Pharmaceuticals (CNAT) Misses Q2 EPS by 2c

Conatus Pharmaceuticals (NASDAQ: CNAT) reported Q2 EPS of ($0.19), $0.02 worse than the analyst estimate of ($0.17). Revenue for the quarter came in at $10 million versus the consensus estimate of $7.75 million.

Cash, cash equivalents and marketable securities were $88.2 million at June 30, 2017, compared with $77.0 million at December 31, 2016, and a projected year-end 2017 balance of between $55 million and $65 million. The company believes its financial resources, including a $7.0 million license option exercise payment received in July 2017 and anticipated expense reimbursements related to the Novartis agreement, are sufficient to maintain operations and ongoing emricasan clinical development activities through the end of 2019, as well as to fund anticipated pipeline expansion activities.

For earnings history and earnings-related data on Conatus Pharmaceuticals (CNAT) click here.

You May Also Be Interested In

• BJ's Wholesale Club (BJ) Tops Q2 EPS by 19c, Beats on Revenue; Offers FY27 EPS Guidance
• Analog Devices (ADI) Tops Q3 EPS by 11c, Beats on Revenue; Offers Q4 Guidance
• Opera Limited (OPRA) Misses Q2 EPS by 1c ; Offers Guidance